Months after Imfinzi combo flops, AstraZeneca wins NICE endorsement as lung cancer monotherapy - Endpoints News

Months after Imfinzi combo flops, AstraZeneca wins NICE endorsement as lung cancer monotherapy  Endpoints News

AstraZeneca's big bet on a combination of its checkpoint inhibitor Imfinzi and in-house CTLA-4 drug has proved exceedingly costly, but the British drugmaker ...



Comments

Popular posts from this blog

Oncology: The disease, dynamics & challenges of market research

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Lung Cancer Among People Who Never Smoked